Results 11 to 20 of about 3,840 (115)
Cabergoline Use and Pregnancy Outcomes: A Systematic Review [PDF]
Birth Defects Research, Volume 117, Issue 3, March 2025.ABSTRACT Introduction Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated.
Anne‐Sophie Otis +4 more
wiley +2 more sources
Microprolactinoma Growth During Pregnancy With Pituitary Tumor Apoplexy: Case Report and Review of the Literature [PDF]
Case Reports in Endocrinology, Volume 2025, Issue 1, 2025.Prolactinomas are the most prevalent subtype of pituitary adenomas and represent one of the leading etiological factors responsible for amenorrhea and infertility in women. The primary therapeutic approach entails the use of dopamine agonists, which effectively restore fertility.
Lucia Introini +5 more
wiley +2 more sources
Equine Veterinary Education, Volume 37, Issue 4, Page 202-209, April 2025.Summary Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are being used increasingly in equine practice. While there is emerging clinical evidence of the safety and efficacy of these drugs, there are currently no reports to document owner experiences with treatment.
Tania Sundra +4 more
wiley +1 more source
Advanced Science, Volume 12, Issue 12, March 27, 2025.The authors uncovered that targeting the constitutive androstane receptor (CAR) might decelerate the aging process. Employing models like C. elegans and mice, they determined that CAR agonists CITCO and TCPOBOP can extend both the lifespan and healthspan.
Jing Yu +12 more
wiley +1 more source
Fetal death: Expert consensus of the French College of Obstetricians and Gynecologists
International Journal of Gynecology &Obstetrics, Volume 168, Issue 3, Page 999-1008, March 2025.Abstract Fetal death is defined as the spontaneous cessation of cardiac activity after 14 weeks gestational age (GA). Regarding prevention of fetal death in the general population, it is not recommended to counsel or prescribe rest, aspirin, vitamin A, vitamin D, or micronutrient supplementation; systematically look for nuchal cord during prenatal ...
Charles Garabedian +19 more
wiley +1 more source
Acta Crystallographica Section E Structure Reports Online, 2004 A new crystal structure of cabergoline (C26H37N5O2), polymorph form VII, is reported. It crystallizes in the same space group, P21, as the more stable form I, but there are two independent molecules in form VII. The molecular packing and the hydrogen-bond networks are, consequently, completely different.
Roman Bednář +5 more
openaire +2 more sources
Pharmacoepidemiology and Drug Safety, Volume 34, Issue 3, March 2025.ABSTRACT Background Direct Healthcare Professional Communications (DHPCs) are an important risk minimisation measure. Their effect has been shown to be variable and has been measured using different outcomes and study populations. Depending on the content of the message, the optimal outcome to measure a direct effect of the DHPC can differ.
Esther de Vries +3 more
wiley +1 more source
Cancer Science, Volume 116, Issue 3, Page 783-791, March 2025.We conducted a population‐based case–control study from Taiwan, linking Health and Welfare Data Science Center data to the Taiwan Cancer Registry to evaluate the potential repurposing of anti‐parkinsonian drugs for pancreatic cancer treatment. The findings revealed a statistically significant association of the administration with specific anti ...
Hsuan‐Chia Yang +8 more
wiley +1 more source
Pegvisomant and cabergoline combination therapy in acromegaly
Pituitary, 2012 Combination with cabergoline may offer additional benefits to acromegalic patients on pegvisomant monotherapy. We evaluated the safety and efficacy profile of this combination and investigated the determinants of response. An observational, retrospective, cross-sectional study.
Amalia-Elisa Paniagua +8 more
openaire +5 more sources
Cabergoline Treatment in Invasive Giant Prolactinoma [PDF]
Clinical Medicine Insights: Case Reports, 2014 Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive giant prolactinoma.
Mussa H. Almalki, Sadeem Alsubaie
openaire +4 more sources